Radio and PodcastRadio and PodcastLive Radio & Podcasts
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? artwork
Science & Medicine

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

GRACEcast by Howard (Jack) West, MD

Jul 17, 201407:28Science & Medicine

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

Related Episodes

Continue listening to more episodes from GRACEcast.

Management of Rare Kidney Tumors

Jul 29, 2014 - 01:55

What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for...